A registry study from Lund University in Sweden shows a possible increased risk of basal cell carcinoma with certain blood pressure medications. Because the risk increase is relatively low, 9% or lower, the researchers do not recommend treatment discontinuation. Instead, physicians should inform their patients that extra sun protection may be needed. The study’s lead author, Johan Kappelin, PhD, is a senior consultant at the dermatology clinic in Landskrona, Sweden. “Basal c

Durable, ongoing near-complete response to nivolimab + relatlimab in a 64-year-old with locally-advanced BCC after resistance to 26 weeks of nivolimab alone. Photo by: Evan Lipson, M.D. A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in treatment. Results from the phase 2 clinical trial (NCT03521830), presented Oct. 20 at the European Society

Dr. Lee Wheless, photo courtesy Vanderbilt University Medical Centre Dermatologists have recommended the dietary supplement nicotinamide...

Global maps of age-standardized incidence rate attributable to (A) cutaneous melanoma, (B) squamous cell carcinoma, and (C) basal cell...

The Dermatology Association of Radiation Therapy (DART), a U.S. national non-profit medical society, has published new clinical...

New research from the Mayo Clinic suggests patients with lower-limb lymphedema had twice the risk of developing skin cancer than patients...

In a new study, correctly-performed combined curettage and cryosurgery with standardized protocols provided excellent clinical clearance...

New findings from the University of Gothenburg in Sweden show that methotrexate (MTX) use is associated with a higher risk of skin cancer...